ABSTRACT
Introducción. Los anticuerpos antifosfolípidos se han encontrado elevados en pacientes con preeclampsia/eclamplsia. Objetivo. Determinar la presencia de anticuerpos anticardiolipina en pacientes con preeclampsia/eclampsia. Pacientes y métodos. Estudiamos prospectivamente 65 pacientes, 35 con preeclampsia/eclampsia (grupo problema, A) y 30 con embarazo normal (grupo control, B) en una UCI. Se efectuó determinación en sangre de IgM e IgG utilizando el método modificado de Harris al segundo y tercer trimestre de embarazo en los dos grupos. Resultados. Encontramos al 2o. y 3er. trimestre de embarazo: en el grupo A, lgG 1.3 ñ 0.9 U y 1.52 ñ 1.1, respectivamante (cuatro pacientes) y la lgM fue de 2.2 ñ 0.9 U y 2.06 ñ 0.81 U (nueve pacientes). En el grupo B (30 pacientes) la lgG fue 1.2 ñ 0.7 U y 0.2 ñ 0.1 U, y la lgM 2.1 ñ U y 1.7 ñ 1 U en los mismos periodos. Conclusión. Los anticuerpos anticardiolipinas se elevan frecuentemente en pacientes con preeclampsia/eclampsia
Subject(s)
Humans , Female , Pregnancy , Antibodies, Anticardiolipin/analysis , Antibodies, Anticardiolipin/blood , Eclampsia/blood , Eclampsia/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Pre-Eclampsia/blood , Pre-Eclampsia/immunology , Pregnancy Complications/etiology , Pregnancy Complications/immunology , Pregnancy Trimester, First/cerebrospinal fluid , Pregnancy Trimester, Second/immunology , Pregnancy Trimester, Third/immunologyABSTRACT
A cross-sectional, sero-epidemiological survey of the prevalence of antibodies to TORCH agents during various stages of gestation revealed an overall rate of 13-15 percent having antibodies to Toxoplasma gondii; 85-87 percent, to rubella ; 79-81 percent, to herpes simplex virus (HSV); 100 percent, to cytomegalovirus (CMV); 82-86 percent, to human herpes virus type 6 (HHV-6); 1-2 percent, to hepatitis C virus (HCV). None of human T lymphotropic virus type I (HTLV-I) antibody was detected, and a prevalence of hepatitis B surface antigen (HBsAg) was 6 percent. Although a tendency was noted towards an increase of antibody detection to each TORCH agent as gestation progressed, a statistically significant increase in antibodies titer and specific IgM antibody was found with regard to CMV. These results suggest an increase in CMV infection or reactivation during pregnancy whereas an increase in the other TORCH infections was not obvious.